Market Cap | 9.56B | P/E | - | EPS this Y | -14.30% | Ern Qtrly Grth | - |
Income | -150.56M | Forward P/E | -44.33 | EPS next Y | -13.00% | 50D Avg Chg | 6.00% |
Sales | 4M | PEG | - | EPS past 5Y | - | 200D Avg Chg | 77.00% |
Dividend | N/A | Price/Book | 13.67 | EPS next 5Y | - | 52W High Chg | - |
Recommedations | 2.50 | Quick Ratio | 36.90 | Shares Outstanding | 47.81M | 52W Low Chg | 654.00% |
Insider Own | 16.61% | ROA | -20.06% | Shares Float | 33.23M | Beta | -0.49 |
Inst Own | 81.01% | ROE | -33.30% | Shares Shorted/Prior | 4.68M/4.90M | Price | 199.92 |
Gross Margin | - | Profit Margin | - | Avg. Volume | 1,299,307 | Target Price | 190.00 |
Oper. Margin | -4,064.73% | Earnings Date | May 13 | Volume | Change | 0.00% |
Prometheus Biosciences, Inc., a clinical-stage biotechnology company, engages in the discovery, development, and commercialization of novel therapeutics for the treatment of inflammatory bowel diseases (IBD). Its lead product includes PRA023, a humanized IgG1 monoclonal antibody (mAb), which is in Phase IIa clinical trial for the treatment of ulcerative colitis and Crohn's disease, as well as systemic sclerosis-associated interstitial lung disease. The company also develops PR300, a G-protein coupled receptor modulator for IBD and potentially other immune-mediated diseases; PRA052, an anti-CD30L mAb for IBD; PR1100, an anti-cytokine receptor mAb for IBD and other immune-mediated diseases; and PR2100, an anti-inflammatory cytokine mAb for IBD, and inflammatory and fibrotic diseases. It has a diagnostics development and collaboration agreement with Takeda Pharmaceutical Company Limited; co-development and manufacturing agreement with Dr. Falk Pharma GmbH for PRA052; license agreement with Cedars-Sinai Medical Center; and strategic collaboration with Millennium Pharmaceuticals, Inc. The company was formerly known as Precision IBD, Inc. and changed its name to Prometheus Biosciences, Inc. in October 2019. Prometheus Biosciences, Inc. was incorporated in 2016 and is headquartered in San Diego, California. As of June 16, 2023, Prometheus Biosciences, Inc. operates as a subsidiary of Merck & Co., Inc.
RBC Capital | Sector Perform | May 10, 23 |
Jefferies | Hold | May 10, 23 |
Wells Fargo | Equal-Weight | Apr 18, 23 |
Credit Suisse | Neutral | Apr 18, 23 |
RBC Capital | Sector Perform | Apr 18, 23 |
Piper Sandler | Neutral | Apr 18, 23 |
Guggenheim | Neutral | Apr 17, 23 |
Stifel | Hold | Apr 17, 23 |
Guggenheim | Buy | Mar 6, 23 |
Insider Trades | Relationship | Date | Transactions | Cost($) | #Shares | Value($) | #Share Own | SEC Form 4 |
---|---|---|---|---|---|---|---|---|
McKenna Mark C. | Chairman, President.. Chairman, President & CEO | Jun 02 | Option | 2.3 | 122,531 | 281,821 | 178,036 | 06/02/23 |
Marshall Keith W | Chief Financial Offi.. Chief Financial Officer | Jun 02 | Option | 3.10 | 78,162 | 242,302 | 87,973 | 06/02/23 |
Marshall Keith W | Chief Financial Offi.. Chief Financial Officer | Apr 05 | Sell | 108.42 | 10,000 | 1,084,200 | 9,811 | 04/07/23 |
Marshall Keith W | Chief Financial Offi.. Chief Financial Officer | Apr 05 | Option | 3.7 | 10,000 | 37,000 | 19,811 | 04/07/23 |
McKenna Mark C. | Chairman, President.. Chairman, President & CEO | Mar 15 | Sell | 116.14 | 25,000 | 2,903,500 | 55,144 | 03/17/23 |
McKenna Mark C. | Chairman, President.. Chairman, President & CEO | Mar 15 | Option | 2.9 | 25,000 | 72,500 | 80,144 | 03/17/23 |
Marshall Keith W | Chief Financial Offi.. Chief Financial Officer | Mar 06 | Sell | 122.13 | 10,000 | 1,221,300 | 9,811 | 03/08/23 |
Marshall Keith W | Chief Financial Offi.. Chief Financial Officer | Mar 06 | Option | 3.7 | 10,000 | 37,000 | 19,811 | 03/08/23 |
Cedars Sinai Intellectual Prop... | 10% Owner 10% Owner | Mar 08 | Sell | 114.59 | 865,000 | 99,120,350 | 4,001,132 | 03/08/23 |
McKenna Mark C. | Chairman, President.. Chairman, President & CEO | Mar 01 | Sell | 125.2 | 11,320 | 1,417,264 | 55,144 | 03/03/23 |
McKenna Mark C. | Chairman, President.. Chairman, President & CEO | Mar 01 | Option | 3.7 | 11,320 | 41,884 | 65,764 | 03/03/23 |
Marshall Keith W | Chief Financial Offi.. Chief Financial Officer | Feb 15 | Sell | 119.38 | 5,000 | 596,900 | 9,811 | 02/17/23 |
Marshall Keith W | Chief Financial Offi.. Chief Financial Officer | Feb 15 | Option | 3.7 | 5,000 | 18,500 | 14,811 | 02/17/23 |
McKenna Mark C. | Chairman, President.. Chairman, President & CEO | Feb 15 | Sell | 121.46 | 63,680 | 7,734,573 | 55,144 | 02/17/23 |
McKenna Mark C. | Chairman, President.. Chairman, President & CEO | Feb 15 | Option | 3.43 | 63,680 | 218,422 | 68,824 | 02/17/23 |
Marshall Keith W | Chief Financial Offi.. Chief Financial Officer | Jan 17 | Sell | 119 | 5,000 | 595,000 | 9,811 | 01/19/23 |
Marshall Keith W | Chief Financial Offi.. Chief Financial Officer | Jan 17 | Option | 3.7 | 5,000 | 18,500 | 14,811 | 01/19/23 |
McKenna Mark C. | Chairman, President.. Chairman, President & CEO | Jan 17 | Sell | 118.99 | 25,000 | 2,974,750 | 55,144 | 01/19/23 |
McKenna Mark C. | Chairman, President.. Chairman, President & CEO | Jan 17 | Option | 2.9 | 25,000 | 72,500 | 80,144 | 01/19/23 |